Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen)

Schlegel PN and Walsh PC: Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol. 138:1402–1406. 1987.PubMed/NCBI

Pagano F, Bassi P, Galetti TP, et al: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol. 145:45–50. 1991.

Stenzl A, Cowan NC, De Santis M, et al: Guidelines on bladder cancer: muscle-invasive and metastatic. Eur Assoc Urol. 3:1–59. 2008.

Hong S, Kwak C, Jeon H, Lee E and Lee S: Do vascular, lymphatic, and perineural invasion have prognostic implications for bladder cancer after radical cystectomy? Urology. 65:697–702. 2005. View Article : Google Scholar : PubMed/NCBI

Leissner J, Koeppen C and Wolf H: Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol. 169:955–960. 2003. View Article : Google Scholar : PubMed/NCBI

Patton S, Hall M and Ozen H: Bladder cancer. Curr Opin Oncol. 14:265–272. 2002. View Article : Google Scholar

Shelley MD, Barber J and Wilt T: Surgery versus radiotherapy for invasive bladder cancer. Cochrane Database Syst Rev. CD002079. 2002.

Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 19:666–675. 2001.PubMed/NCBI

Dalbagni G, Genega E, Hashibe M, et al: Cystectomy for bladder cancer: a contemporary series. J Urol. 165:1111–1116. 2001. View Article : Google Scholar : PubMed/NCBI

Frazier H, Robertson J, Dodge R and Paulson D: The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer. 71:3993–4001. 1993. View Article : Google Scholar : PubMed/NCBI

Tran E, Souhami L, Tanguay S and Rajan R: Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer. Am J Clin Oncol. 32:333–337. 2009. View Article : Google Scholar : PubMed/NCBI

Weizer AZ, Joshi D, Daignault S, et al: Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol. 177:1287–1293. 2007. View Article : Google Scholar : PubMed/NCBI

Hoshi S, Shintaku I, Suzuki K, et al: Bladder preservation by internal iliac arterial infusion chemotherapy and irradiation in T3 bladder carcinoma patients over the age of 70 years. Tohoku J Exp Med. 192:249–258. 2000.

Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 5:471–476. 2000.

Rodel C, Grabenbauer GG, Kuhn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 20:3061–3071. 2002. View Article : Google Scholar : PubMed/NCBI

Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 16:3576–3583. 1998.

Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 14:119–126. 1996.

Hagan MP, Winter KA, Kaufman DS, et al: RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 57:665–672. 2003.PubMed/NCBI

Kaufman DS, Winter KA, Shipley WU, et al: Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 73:833–837. 2009. View Article : Google Scholar

Greene FL, Page DL and Fleming ID: AJCC Cancer Staging Manual. 6th edition. Springer Verlag; New York, NY: 2002, View Article : Google Scholar

Ficcara V, Dalpiaz O, Alrabi N, Novara G, Galfano A and Artibani W: Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int. 95:786–790. 2005. View Article : Google Scholar : PubMed/NCBI

Douple EB and Richmond RC: A review of platinum complex biochemistry suggests a rationale for combined platinum-radiotherapy. Int J Radiat Oncol Biol Phys. 8:1335–1339. 1979. View Article : Google Scholar : PubMed/NCBI

Douple EB and Richmond RC: Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II). Int J Radiat Oncol Biol Phys. 8:1369–1372. 1979. View Article : Google Scholar : PubMed/NCBI

Abbott DW, Freeman ML and Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst. 90:978–985. 1998. View Article : Google Scholar : PubMed/NCBI

Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA and Repta AJ: Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 63:1515–1521. 1979.PubMed/NCBI

Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ and Sternson LA: Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther. 29:658–664. 1981. View Article : Google Scholar : PubMed/NCBI